CLINICAL_TRIALS
ClinicalTrials.gov record update
A Pilot Study of Daratumumab (CD38 Antagonist) in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03473730
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:55.171965+00:00
- Published At
- 2025-01-30T00:00:00+00:00
- Record Updated At
- 2025-01-30
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Bladder Urothelial Carcinoma", "Clear Cell Renal Cell Carcinoma", "Malignant Urinary System Neoplasm", "Metastatic Kidney Carcinoma", "Stage IV Renal Cell Cancer AJCC V8"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-01-30"- protocolSection.identificationModule.nctId
"NCT03473730"- protocolSection.identificationModule.officialTitle
"A Pilot Study of Daratumumab (CD38 Antagonist) in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["EARLY_PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.